Reta in 2026: Phase 3 Results and Approval Status
2026 is the year reta’s phase 3 results arrived. Retatrutide, the triple GLP-1, GIP and glucagon receptor agonist known as reta or GLP-3, now has three phase 3 trials published in the New England Journal of Medicine and The Lancet, with mean weight loss of up to 25.0% at 80 weeks in adults with obesity. This page sets out what each trial found, the figures as published, where approval stands in October 2026, and what is still to come.
Findings
- Obesity: in 2,339 adults over 80 weeks, reta’s 12 mg group lost 25.0% of body weight on average, against 3.9% on placebo (N Engl J Med, 2026).
- The same trial reported less knee osteoarthritis pain and fewer sleep apnea events in the participants who had those conditions.
- Obesity with type 2 diabetes: 18.8% on 12 mg against 5.1% on placebo at 80 weeks in 1,152 adults (Lancet, 2026).
- Type 2 diabetes: HbA1c fell by up to 1.94 points and weight by up to 15.3% in 40 weeks, as a single agent (Lancet, 2026).
- As of October 2026 reta holds no Health Canada or FDA approval; a US filing is planned for the first quarter of 2027.
View product →The reta obesity trial (NEJM, 2026)
The largest reta trial so far randomised 2,339 adults with obesity and without diabetes to weekly reta at 4, 9 or 12 mg, or placebo, for 80 weeks. Using the intention-to-treat analysis, mean body weight changed by 17.6%, 23.7% and 25.0% on the three doses, against 3.9% on placebo (Jastreboff et al., N Engl J Med, 2026).
The trial also carried two built-in sub-studies. In 574 participants with knee osteoarthritis, the pain score fell by 3.4, 3.9 and 4.1 points on the three doses against 2.5 on placebo. In 243 participants with obstructive sleep apnea, breathing interruptions fell by 22.8, 34.3 and 32.1 events per hour against 9.6 on placebo. The most common adverse events were gastrointestinal.
When the trial first reported in May 2026, the headline figure was 28.3% on 12 mg. That number came from a different analysis, which estimates the effect in participants who stayed on treatment; the published intention-to-treat figure of 25.0% counts everyone randomised. Both describe the same trial.
Reta in obesity with type 2 diabetes (Lancet, 2026)
This trial enrolled 1,152 adults with type 2 diabetes and a BMI of 27 or higher at 92 centres in eight countries. Mean baseline BMI was 38.2 and mean HbA1c 7.71%, and 92% were already taking oral diabetes medication. At 80 weeks, body weight changed by 11.9% (4 mg), 16.8% (9 mg) and 18.8% (12 mg), against 5.1% on placebo, alongside better glycaemic control; 84% of participants completed the study drug (Bellido et al., Lancet, 2026). Weight loss in people with type 2 diabetes characteristically runs below non-diabetic cohorts, which is the context for comparing these figures with the obesity trial. Gastrointestinal events were the most frequent adverse events.
Reta as a single agent in type 2 diabetes (Lancet, 2026)
The first diabetes trial randomised 537 adults whose type 2 diabetes was not controlled by diet and exercise, at 48 sites in the United States, Mexico and India, to reta 4, 9 or 12 mg or placebo for 40 weeks. HbA1c fell by 1.69, 1.86 and 1.94 points against 0.81 on placebo, from a baseline of 7.9%. Body weight fell 11.5%, 13.9% and 15.3% against 2.6%. Ninety-one percent completed treatment, and no severe hypoglycaemia was reported (Bajaj et al., Lancet, 2026).
Reta in obesity with cardiovascular disease
A fourth phase 3 trial enrolled about 1,950 adults with a BMI of 35 or higher and established cardiovascular disease, and finished its primary phase in April 2026 (ClinicalTrials.gov NCT05882045). Topline results released in July 2026 reported 80-week weight loss of 21.6% (9 mg) and 22.6% (12 mg) against 3.2% on placebo. As of October 2026 the full results had not yet appeared in a journal.
What else reta’s 2026 research added
A 2026 analysis of the two phase 2 trials looked beyond weight. In adults with obesity and no diabetes, reta was associated with reductions of up to 26.9% in non-HDL cholesterol, 24.2% in apolipoprotein B and 54.8% in high-sensitivity C-reactive protein, a marker of inflammation (Ruotolo et al., Diabetes Obes Metab, 2026). The earlier liver-fat findings are covered in peptides for fatty liver.
| Reta trial | Published | Adults | Length | Headline result (12 mg vs placebo) |
|---|---|---|---|---|
| Obesity | N Engl J Med, Sept 2026 | 2,339 | 80 weeks | Weight down 25.0% vs 3.9% |
| Obesity with type 2 diabetes | Lancet, Oct 2026 | 1,152 | 80 weeks | Weight down 18.8% vs 5.1% |
| Type 2 diabetes, single agent | Lancet, June 2026 | 537 | 40 weeks | HbA1c down 1.94 vs 0.81 points |
| Obesity with cardiovascular disease | Topline only, July 2026 | About 1,950 | 80 weeks | Weight down 22.6% vs 3.2% |
The doses above refer to a pharmaceutical product given under trial protocols and are reported as published research findings. Reta supplied by Vistara Labs is for laboratory research use only.
Early access to reta
In August 2026 a compassionate-use route opened in the United States, through which a limited group of patients can be considered for reta before approval, with their physician making the request (Brown, BMJ, 2026). It is an expanded-access arrangement for individual cases, not an approval, and it runs under US rules.
Where reta approval stands
- Canada: retatrutide does not appear in Health Canada’s Drug Product Database as of October 2026, so it holds no Canadian drug authorization.
- United States: not approved by the FDA. The developer has said it plans to file in the first quarter of 2027, after completing its manufacturing and quality package.
- Head-to-head with tirzepatide: a phase 3 trial of about 800 adults comparing reta directly with tirzepatide has an estimated primary completion date of November 2026 (ClinicalTrials.gov NCT06662383). Until it reports, the comparison rests on separate trials, covered in reta vs tirzepatide.
What this means for reta research supply in Canada
The trials settle whether the triple-agonist mechanism is worth studying, and they do not change the status of reta as a research material. Reta supplied for laboratory work is a research compound, not the pharmaceutical product tested in these trials. The legal position is set out in Is Reta Legal in Canada?, and sourcing, certificates and our Retatrutide (GLP-3) vials are covered in Where to Buy Reta in Canada.
Frequently asked questions
Is reta approved anywhere?
Not in Canada or the United States as of October 2026. Retatrutide is not in Health Canada’s Drug Product Database, and a US filing is planned for the first quarter of 2027.
How much weight did people lose in the reta phase 3 trials?
In the 2026 NEJM obesity trial of 2,339 adults, mean weight loss at 80 weeks was 25.0% on 12 mg against 3.9% on placebo. In adults with obesity and type 2 diabetes it was 18.8% against 5.1%.
Why do some reports say reta produced 28.3% weight loss?
28.3% was the May 2026 topline figure from an on-treatment analysis. The published NEJM paper reports 25.0% using intention-to-treat, which counts every participant randomised. Both come from the same trial.
Has reta been compared with tirzepatide directly?
Not in published results yet. A head-to-head phase 3 trial of about 800 adults has an estimated primary completion date of November 2026.
Where can I buy reta in Canada?
Vistara Labs supplies reta as Retatrutide (GLP-3), lyophilised research vials shipped from within Canada by Canada Post Xpresspost.
Sources: Jastreboff AM et al. Retatrutide, a triple hormone receptor agonist, for treatment of obesity. N Engl J Med. 2026. PMID 42814954. Bellido V et al. Retatrutide in adults with obesity and type 2 diabetes: a phase 3 trial. Lancet. 2026. PMID 42810372. Bajaj HS et al. Efficacy and safety of retatrutide in people with type 2 diabetes and inadequate glycaemic control with diet and exercise: a phase 3 trial. Lancet. 2026. PMID 42250575. Ruotolo G et al. Retatrutide-associated improvements in cardiovascular risk biomarkers in adults with obesity with or without type 2 diabetes. Diabetes Obes Metab. 2026. PMID 42608321. Brown C. BMJ. 2026. PMID 42567543. ClinicalTrials.gov NCT05882045 and NCT06662383. Health Canada Drug Product Database, searched October 2026.
More on this: Reta Weight-Loss Trials: What the Data Shows.
All products supplied by Vistara Labs are intended for laboratory research use only. They are not drugs, are not approved for human or veterinary use, and are not intended to diagnose, treat, cure or prevent any condition. Nothing on this page constitutes medical advice or guidance for use in humans.
References
Retatrutide has been evaluated in randomised, placebo-controlled human trials through phase 3.
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 TrialRandomised, double-blind, placebo-controlled phase 2 obesity trial, 48 weeks.
- Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial conducted in the USARandomised, double-blind, placebo- and active-controlled phase 2 trial; 281 participants with type 2 diabetes.
- Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trialRandomised phase 2a substudy; 98 participants with metabolic dysfunction-associated steatotic liver disease.
- Efficacy and safety of retatrutide, a GIP, GLP-1, and glucagon receptor agonist, in people with type 2 diabetes and inadequate glycaemic control with diet and exercise: a double-blind, randomised, phase 3 trialDouble-blind randomised phase 3 trial in type 2 diabetes.
Links open the study record on PubMed so the source can be checked directly. Listing a study is not a claim that its findings apply to any other use, product or route of administration. Research use only.